Pegasys/Copegus combo pack clears FDA
Executive Summary
Roche will continue to sell Pegasys (peginterferon alpha-2a) and Copegus (ribavirin) separately following FDA's June 4 approval of a co-packaged version. Roche is not announcing a launch date or pricing information for the combination. Availability of a co-packaged product could lessen the likelihood that patients will combine Pegasys with generic equivalents to Schering-Plough's Rebetol (ribavirin) (1"The Pink Sheet" April 12, 2004, p. 38)...
You may also be interested in...
Ribavirin ANDAs Clear FDA; Schering Goes Generic Too
Three Rivers/Par, Sandoz and Schering-Plough are launching their ribavirin generics at a 10% discount to Schering's Rebetol
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.